Soluble CD44v6 is not a sensitive tumor marker in patients with head and neck squamous cell cancer

Anticancer Research

Volumn 25, Issue 4, 2005, Pages 2821-2826

  Andratschke, Michaela ^a,c   Chaubal, Sarita ^a   Pauli, Christof ^a   Mack, Brigitte ^a   Hagedorn, Hjalmar ^a   Wollenberg, Barbara ^b  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

CD44v6; Clinical prognostic factor; Neoplasm; SCCHN; Serum tumor marker; Soluble CD44; Squamous cell carcinoma of the head and neck

Indexed keywords

SOLUBLE CD4 ANTIGEN; TUMOR MARKER;

ANTIGEN EXPRESSION; ARTICLE; BLOOD SAMPLING; CANCER CLASSIFICATION; CANCER GRADING; CANCER STAGING; CIGARETTE SMOKING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; DYSPLASIA; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM; HEAD AND NECK CANCER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TUMOR CELL;

ANTIGENS, CD44; CARCINOMA, SQUAMOUS CELL; CELL DIFFERENTIATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLYCOPROTEINS; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM INVASIVENESS; NEOPLASM STAGING; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 22944478629     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Bourguignon LYW, Zhu D and Zhu H: CD44 isoform-cytoskeleton interaction in oncogenic signaling and tumor progression. Front Biosci 3: D637-649, 1998.
2. Carinci F, Stabellini G, Calvitti M, Pelucchi S, Targa L, Farina A, Pezzetti F and Pastore A: CD44 as prognostic factor in oral and oropharyngeal squamous cell carcinoma. J Craniofac Surg 13(1): 85-89, 2002.
3. Fonseca I, Pereira T, Rosa-Santos J and Soares J: Expression of CD44 isoforms in squamous cell carcinoma of the border of the tongue: a correlation with histological grade, pattern of stromal invasion, and cell differentiation. J Surg Oncol 76(2): 115-120, 2001.
4. Fox SB, Gatter KC, Jackson DG, Screaton GR, Bell MV, Bell JI, Harris AL, Simmons D and Fawcett J: CD44 and cancer screening. Lancet 342(8870): 548-549, 1993.
5. Gadducci A, Ferdeghini M, Cosio S, Annicchiarico C, Fanucchi A, Prontera C, Bianchi R and Genazzani AR: The serum assay of soluble CD44 standard (sCD44-st), CD44 splice variant 5 (sCD44-v5), and CD44 splice variant 6 (sCD44-v6) in patients with cervical cancer. Anticancer Res 18(1B): 537-539, 1998.
6. Gansauge F, Gansauge S, Rau B, Scheiblich A, Poch B, Schoenberg MH and Beger HG: Low serum levels of soluble CD44 variant 6 are significantly associated with poor prognosis in patients with pancreatic carcinoma. Cancer 80(9): 1733-1739, 1997.
7. Givehchian M, Woerner SM, Lacroix J, Zoller M, Drings P, Becker H, Kayser K, Ridder R and von Knebel Doeberitz M: Expression of CD44 splice variants in normal respiratory epithelium and bronchial carcinomas: no evidence for altered CD44 splicing in metastasis. Oncogene 12(5): 1137-1144, 1996.
8. Güler G, Sarac S, Uner A, Karabulut E, Ayhan A and Hiroshi O: Prognostic value of CD44 variant 6 in laryngeal epidermoid carcinomas. Arch Otolaryngol Head Neck Surg 128(4): 393-397, 2002.
9. Harn HJ, Ho LI, Shyu RY, Yuan JS, Lin FG, Young TH, Liu CA, Tang HS and Lee WH: Soluble CD44 isoforms in serum as potential markers of metastatic gastric carcinoma. J Clin Gastroenterol 22(2): 107-110, 1996.
10. Hefler L, Tempfer C, Haeusler G, Kucera E, Mayerhofer K, Zeillinger R, Reinthaller A and Kainz C: Cytosol concentrations of CD44 isoforms in breast cancer tissue. Int J Cancer 23, 79(5): 541-545, 1998.
11. Herrera-Gayol A and Jothy S: Adhesion proteins in the biology of breast cancer: contribution of CD44. Exp Mol Pathol 66(2): 149-156, 1999.
12. Jackson DG, Prevo R, Clasper S and Banerji S: LYVE-1, the lymphatic system and tumor lymphangiogenesis. Trends Immunol 22(6): 317-321, 2001.
13. Kainz C, Tempfer C, Kohlberger P, Janisch S, Koelbl H, Gitsch G and Breitenecker G: Immunohistochemical detection of adhesion molecule CD44 splice variants in lymph node metastases of cervical cancer. Int J Cancer 69(3): 170-173, 1996.
14. Kanke M, Fujii M, Kameyama K, Kanzaki J, Tokumaru Y, Imanishi Y, Tomita T and Matsumura Y: Role of CD44 variant exon 6 in invasion of head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 126(10): 1217-1223, 2000.
15. Korabiowska M, Brinck U, Honig J, Mora O, Bartkowski S and Schauer A: CD44: a marker of metastases of head and neck melanomas. In Vivo 9(3): 253-256, 1995.
16. Martin S, Jansen F, Bokelmann J and Kolb H: Soluble CD44 splice variants in metastasizing human breast cancer. Int J Cancer 74(4): 443-445, 1997.
17. Mizera-Nyczak E, Dyszkiewicz W, Heider KH and Zeromski J: Isoform expression of CD44 adhesion molecules, Bcl-2, p53 and Ki-67 proteins in lung cancer. Tumour Biol 22(1): 45-53, 2001.
18. Mulder JW, Wielenga VJ, Polak MM, van den Berg FM, Adolf GR, Herrlich P, Pals ST and Offerhaus GJ: Expression of mutant p53 protein and CD44 variant proteins in colorectal tumorigenesis. Gut 36(1): 76-80, 1995.
19. Naor D, Sionov RV and Ish-Shalom D: CD44: structure, function, and association with the malignant process. Adv Cancer Res 71: 241-319, 1997.
20. Nerlich A and Schleicher E: Immunohistochemical localization of extracellular matrix components in human diabetic glomerular lesions. Am J Pathol 139(4): 889-899, 1991.
21. Ostwald J, Pracht O, Rhode E and Kramp B: Sind die Produkte der Exons v5 und v6 von CD44 Marker für die Metastasierung von Larynxkarzinomen? Laryngo-Rhino-Otol 76: 295-299, 1997.
22. Rudy W, Hofmann M, Schwartz-Albiez R, Zoller M, Heider KH, Ponta H and Herrlich P: The two major CD44 proteins expressed on a metastatic rat tumor cell line are derived from different splice variants: each one individually suffices to confer metastatic behavior. Cancer Res 53(6): 1262-1268, 1993.
23. Salles G, Zain M, Jiang WM, Boussiotis VA and Shipp MA: Alternatively spliced CD44 transcripts in diffuse large-cell lymphomas: characterization and comparison with normal activated B cells and epithelial malignancies. Blood 82(12): 3539-3547, 1993.
24. Seiter S, Tilgen W, Herrmann K, Schadendorf D, Patzelt E, Moller P and Zoller M: Expression of CD44 splice variants in human skin and epidermal tumours. Virchows Arch 428(3): 141-149, 1996.
25. Sikorska B, Danilewicz M and Wagrowska-Danilewicz M: Prognostic significance of CD44v6 and nm23 protein immunoexpression in laryngeal squamous cell carcinoma. Pol J Pathol 53(1): 17-24, 2002.
26. Sliutz G, Tempfer C, Winkler S, Kohlberger P, Reinthaller A and Kainz C: Immunohistochemical and serological evaluation of CD44 splice variants in human ovarian cancer. Br J Cancer 72(6): 1494-1497, 1995.
27. Soukka T, Salmi M, Joensuu H, Hakkinen L, Sointu P, Koulu L, Kalimo K, Klemi P, Grenman R and Jalkanen S: Regulation of CD44v6-containing isoforms during proliferation of normal and malignant epithelial cells. Cancer Res 57(11): 2281-2289, 1997.
28. Stoll C, Baretton G, Soost F, Terpe HJ, Domide P and Lohrs U: Prognostic importance of the expression of CD44 splice variants in oral squamous cell carcinomas. Oral Oncol 35(5): 484-489, 1999.
29. Takigawa N, Segawa Y, Mandai K, Takata I and Fujimoto N: Serum CD44 levels in patients with non-small cell lung cancer and their relationship with clinicopathological features. Lung Cancer 18(2): 147-157, 1997.
30. Terpe HJ, Storkel S, Zimmer U, Anquez V, Fischer C, Pantel K and Gunthert U: Expression of CD44 isoforms in renal cell tumors. Positive correlation to tumor differentiation. Am J Pathol 148(2): 453-463, 1996.
31. Van Hal NL, van Dongen GA, Stigter-van Walsum M, Snow GB and Brakenhoff RH: Characterization of CD44v6 isoforms in head-and-neck squamous-cell carcinoma. Int J Cancer 82(6): 837-845, 1999 (a).
32. Weg-Remers S, Hildebrandt U, Feifel G, Moser C, Zeitz M and Stallmach A: Soluble CD44 and CD44v6 serum levels in patients with colorectal cancer are independent of tumor stage and tissue expression of CD44v6. Am J Gastroenterol 93(5): 790-794, 1998.
33. Yamamichi K, Uehara Y, Kitamura N, Nakane Y and Hioki K: Increased expression of CD44v6 mRNA significantly correlates with distant metastasis and poor prognosis in gastric cancer. Int J Cancer 79(3): 256-262, 1998.